57,300 Shares in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Bought by Garden State Investment Advisory Services LLC

Garden State Investment Advisory Services LLC purchased a new stake in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Analysts Set New Price Targets

Separately, Maxim Group reaffirmed a “hold” rating on shares of Virpax Pharmaceuticals in a report on Wednesday, October 9th.

Virpax Pharmaceuticals Stock Down 2.4 %

Virpax Pharmaceuticals stock opened at $0.45 on Tuesday. Virpax Pharmaceuticals, Inc. has a 52 week low of $0.36 and a 52 week high of $5.48. The business’s 50-day moving average price is $0.62 and its 200 day moving average price is $0.80.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.